Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Outcomes in AL Amyloidosis: A Single Institution Experience

Diana Basali, MD, Jennifer Tran, DO, Wei Wei, MS, Sherry Fada, Brittany Lewis, Jason Valent, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-140619

Published: 2020

Journal Articles

Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

Jason Valent, MD, John Silowsky, RN BSN, Michael R. Kurman, MD, Eileen Daniel, Janet Jobes, Mark Harnett, MS, Margaret Ziola, MD, Jessica Roviwong, Sherry Fada, Michael Spector, BS, Susan B. Sobolov, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139323

Published: 2020

Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-139438

Published: 2020

Journal Articles

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, PhD, Anand D. Tiwari, PhD, Xiaorong Gu, PhD, Jason Valent, MD, Jaroslaw Maciejewski, PhD, Frederic Joel Reu, James G Phillips, PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142847

Published: 2020

Journal Articles

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-137235

Published: 2020

Journal Articles

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Jason Valent, MD, Alex V. Mejia Garcia, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Nathaniel Rosko, PharmD, Christy J. Samaras, DO, Matt Kalaycio, MD, Faiz Anwer, MD, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137525

Published: 2020

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Rajshekar Chakraborty, MD, Lisa Rybicki, MS, Megan Nakashima, MD, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Christy J. Samaras, DO, Nathaniel Rosko, PharmD, Jason Valent, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 4359.

https://doi.org/10.1182/blood-2019-123861

Published: 2019

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Fahrettin Covut, MD, Ramsha Ahmed, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Alex V. Mejia Garcia, MD, Dana E Angelini, MD, Beth M. Faiman, PhDCNP, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Saveta Mathur, CNP, Kimberly Hamilton, APRN/PA, Nathaniel Rosko, PharmD, Jason Valent, MD, Jack Khouri, MD

Blood (2019) 134 (Supplement_1): 3148.

https://doi.org/10.1182/blood-2019-131400

Published: 2019

Journal Articles

Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Ehsan Malek, MD, Byung-Gyu Kim, PhD DVM, Jason Valent, MD, James Driscoll, MD PhD, Paolo Caimi, MD, Seong-Jin Kim, PhD, Marcos de Lima, MD, John Letterio, MD

Blood (2018) 132 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2018-99-112449

Published: 2018

Journal Articles

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Sarah S Lee, MD, Nathaniel Rosko, PharmD, Bhumika J. Patel, MD, Madeline Waldron, PharmD, Jackie Tomer, MPH, Roman Goldman, CNP, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Saveta Mathur, CNP, Christy J. Samaras, DO, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2018-99-119979

Published: 2018

Journal Articles

Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis

Rajshekhar Chakraborty, MBBS, Lisa Rybicki, MS, Christy J. Samaras, DO, Beth M. Faiman, PhD CNP, Jason Valent, MD, Navneet S. Majhail, MD MS

Blood (2018) 132 (Supplement 1): 4832.

https://doi.org/10.1182/blood-2018-99-111570

Published: 2018

Journal Articles

Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma

Sarah S Lee, MD, Nathaniel Rosko, PharmD, Pramod Pinnamaneni, MD, Craig Savage, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 4802.

https://doi.org/10.1182/blood-2018-99-120291

Published: 2018

Journal Articles

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Rajshekhar Chakraborty, MBBS, Hien D. Liu, MD, Lisa Rybicki, MS, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Matt Kalaycio, MD, Jack Khouri, MD, Christy J. Samaras, DO, Navneet S. Majhail, MD MS, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2018-99-113114

Published: 2018

Journal Articles

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Jack Khouri, MD, Thapa Bicky, MD, Frederic J. Reu, MD, Christy J. Samaras, DO, Hien D. Liu, MD, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 1819.

https://doi.org/10.1182/blood.V130.Suppl_1.1819.1819

Published: 2017

Journal Articles

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, Saulius Girnius, MD, Saurabh Chhabra, MD, Robert Frank Cornell, MD, Cristina J. Gasparetto, MD, Chatchada Karanes, MD, Matthew A. Lunning, DO, Jeffrey V. Matous, MD, Ruben Niesvizky, MD, Chaim Shustik, MD, Robert K. Stuart, MD, Jason Lih, PhD, Yihua Lee, PhD, Zeena Salman, Thorsten Graef, MD PhD, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 3111.

https://doi.org/10.1182/blood.V130.Suppl_1.3111.3111

Published: 2017

Journal Articles

Response-Adapted Therapy for Newly Diagnosed Myeloma

Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD, Mitchell R. Smith

Blood (2016) 128 (22): 3606.

https://doi.org/10.1182/blood.V128.22.3606.3606

Published: 2016

Journal Articles

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

Hashim Abbas, Lisa A. Rybicki, MS, Frederic J. Reu, MD, Christy Samaras, DO, Mitchell R. Smith, Debbie Hastings, Jason Valent, MD

Blood (2016) 128 (22): 5813.

https://doi.org/10.1182/blood.V128.22.5813.5813

Published: 2016

NARROW

Outcomes in AL Amyloidosis: A Single Institution Experience

Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis

Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Response-Adapted Therapy for Newly Diagnosed Myeloma

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only